ArticleTransplantation2011
Donor graft steatosis influences immunity to hepatitis C virus and allograft outcome after liver transplantation.
Article in Transplantation, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 27 citations in OpenAlex.
- The Propensity of the Human Liver to Form Large Lipid Droplets Is Associated with PNPLA3 Polymorphism, Reduced INSIG1 and NPC1L1 Expression and Increased Fibrogenetic Capacity.International journal of molecular sciences · 2021Article
- Impact of Graft Steatosis on Postoperative Complications after Liver Transplantation.Surgery journal (New York, N.Y.) · 2018Article
- The Impact of Liver Graft Injury on Cancer Recurrence Posttransplantation.Transplantation · 2017Review
- Fibrosing Cholestatic Hepatitis in a Complicated Case of an Adult Recipient After Liver Transplantation: Diagnostic Findings and Therapeutic Dilemma.The American journal of case reports · 2016Article
- Effects of Donor Age and Cold Ischemia on Liver Transplantation Outcomes According to the Severity of Recipient Status.Digestive diseases and sciences · 2016Article
- Management of Hepatitis C Post-liver Transplantation: a Comprehensive Review.Journal of clinical and translational hepatology · 2015Review
- Hepatitis C Recurrence after Orthotopic Liver Transplantation: Mechanisms and Management.Journal of clinical and translational hepatology · 2014Review
- Post-liver transplant hepatitis C virus recurrence: an unresolved thorny problem.World journal of gastroenterology · 2014Review
- Histopathological evaluation of recurrent hepatitis C after liver transplantation: a review.World journal of gastroenterology · 2014Review
- Perioperative blood transfusion affects hepatitis C virus (HCV)-specific immune responses and outcome following liver transplantation in HCV-infected patients.HPB : the official journal of the International Hepato Pancreato Biliary Association · 2014Article
- Donor PNPLA3 rs738409 genotype affects fibrosis progression in liver transplantation for hepatitis C.Hepatology (Baltimore, Md.) · 2014Article
- Living-donor liver transplantation and hepatitis C.HPB surgery : a world journal of hepatic, pancreatic and biliary surgery · 2013Article
- HCV in liver transplantation.Seminars in immunopathology · 2013Article
- Liver transplantation and hepatitis C.International journal of hepatology · 2012Article
- Fibrosing cholestatic hepatitis C in post-transplant adult recipients of liver transplantation.Annals of gastroenterologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 1 institution in 1 country.
Funding
Abstract
backgroundHepatitis C virus (HCV) recurrence after orthotopic liver transplantation (OLT) is universal, often with accelerated allograft fibrosis. Donor liver steatosis is frequently encountered and often associated with poor early postoperative outcome. The aim of this study was to test the hypothesis that allograft steatosis alters immune responses to HCV and self-antigens promoting allograft fibrosis.
methodsForty-eight HCV OLT recipients (OLTr) were enrolled and classified based on amount of allograft macrovesicular steatosis at time of OLT. Group 1: no steatosis (0%-5% steatosis, n=21), group 2: mild (5%-35%, n=16), and group 3: moderate (>35%, n=11). Cells secreting interleukin (IL)-17, IL-10, and interferon gamma (IFN-γ) in response to HCV antigens were enumerated by Enzyme Linked Immunospot Assay. Serum cytokines were measured by Luminex, antibodies to Collagen I, II, III, IV, and V by ELISA.
resultsOLTr of moderate steatotic grafts had the highest incidence of advanced fibrosis in protocol 1 year post-OLT biopsy (10.8% vs. 15.8% vs. 36.6%, r=0.157, P<0.05). OLTr from groups 2 and 3 had increased HCV-specific IL-17 (P<0.05) and IL-10 (P<0.05) with reduced IFN-γ (P<0.05) secreting cells when compared with group 1. This was associated with increase in serum IL-17, IL-10, IL-1β, IL-6, IL-5, and decreased IFN-γ. In addition, there was development of antibodies to Collagen I, II, III and V in OLTr with increased steatosis (P<0.05).
conclusionThe results demonstrate that allograft steatosis influences post-OLT HCV-specific immune responses leading to an IL-17 T-helper response and activation of humoral immune responses to liver-associated self-antigens that may contribute to allograft fibrosis and poor outcome.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.